| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study.
|
J Am Coll Cardiol
|
2005
|
4.39
|
|
2
|
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
|
Hypertension
|
2012
|
2.86
|
|
3
|
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics.
|
Kidney Int
|
2009
|
2.32
|
|
4
|
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
|
Am J Hypertens
|
2010
|
1.90
|
|
5
|
Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study.
|
J Am Coll Cardiol
|
2004
|
1.70
|
|
6
|
Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships.
|
J Neurol Sci
|
2008
|
1.69
|
|
7
|
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.
|
Hypertension
|
2008
|
1.66
|
|
8
|
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension.
|
Kidney Int
|
2002
|
1.64
|
|
9
|
A comparison of serum creatinine-based methods for identifying chronic kidney disease in hypertensive individuals and their siblings.
|
Am J Hypertens
|
2006
|
1.49
|
|
10
|
Risk factor profile for chronic kidney disease is similar to risk factor profile for small artery disease.
|
J Hypertens
|
2011
|
1.45
|
|
11
|
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
|
Am J Hypertens
|
2008
|
1.41
|
|
12
|
Is aortic dilatation an atherosclerosis-related process? Clinical, laboratory, and transesophageal echocardiographic correlates of thoracic aortic dimensions in the population with implications for thoracic aortic aneurysm formation.
|
J Am Coll Cardiol
|
2003
|
1.23
|
|
13
|
Relation of coronary artery disease and cerebrovascular disease with atherosclerosis of the thoracic aorta in the general population.
|
Am J Cardiol
|
2002
|
1.21
|
|
14
|
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
|
Hypertension
|
2005
|
1.18
|
|
15
|
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
|
Hypertension
|
2013
|
1.14
|
|
16
|
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide.
|
Am J Hypertens
|
2003
|
1.09
|
|
17
|
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.
|
Am J Hypertens
|
2005
|
1.08
|
|
18
|
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
|
J Transl Med
|
2012
|
0.97
|
|
19
|
Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance.
|
Diabetes Care
|
2006
|
0.96
|
|
20
|
Personalized medicine for high blood pressure.
|
Hypertension
|
2007
|
0.92
|
|
21
|
Atherosclerotic Vascular Disease Conference: Writing Group V: medical decision making and therapy.
|
Circulation
|
2004
|
0.92
|
|
22
|
Obstructive sleep apnea and aldosterone.
|
Sleep
|
2009
|
0.92
|
|
23
|
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
|
Pharmacotherapy
|
2009
|
0.90
|
|
24
|
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide.
|
Pharmacogenet Genomics
|
2005
|
0.89
|
|
25
|
Ambulatory blood pressure and coronary artery calcification in middle-aged and younger adults.
|
Am J Hypertens
|
2002
|
0.88
|
|
26
|
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects.
|
Am J Hypertens
|
2005
|
0.87
|
|
27
|
Reproducibility of blood pressure response to hydrochlorothiazide.
|
J Clin Hypertens (Greenwich)
|
2002
|
0.86
|
|
28
|
The treatment of hypertension during pregnancy: when should blood pressure medications be started?
|
Curr Cardiol Rep
|
2013
|
0.86
|
|
29
|
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.85
|
|
30
|
Gene markers and antihypertensive therapy.
|
Curr Hypertens Rep
|
2005
|
0.84
|
|
31
|
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
|
Pharmacotherapy
|
2014
|
0.84
|
|
32
|
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study.
|
Physiol Genomics
|
2009
|
0.83
|
|
33
|
Renovascular hypertension: balancing the controversies in diagnosis and treatment.
|
Cleve Clin J Med
|
2005
|
0.80
|
|
34
|
Proper evaluation of asymptomatic microscopic hematuria in the era of evidence-based medicine--progress is being made.
|
Mayo Clin Proc
|
2013
|
0.78
|
|
35
|
C-reactive Protein among Community-Dwelling Hypertensives on Single-agent Antihypertensive Treatment.
|
J Am Soc Hypertens
|
2010
|
0.78
|
|
36
|
Early referral for chronic kidney disease: good for those who need it, but who are they?
|
Mayo Clin Proc
|
2006
|
0.78
|
|
37
|
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
|
Am J Hypertens
|
2013
|
0.77
|
|
38
|
Renal denervation for hypertension.
|
Curr Probl Cardiol
|
2013
|
0.77
|
|
39
|
The new hypertension guidelines from JNC 7: is the devil in the details?
|
Mayo Clin Proc
|
2003
|
0.75
|
|
40
|
Linear dynamic features of ambulatory blood pressure in a population-based study.
|
Blood Press Monit
|
2004
|
0.75
|
|
41
|
Diagnostic evaluation: Initial evaluation: laboratory testing.
|
J Am Soc Hypertens
|
2014
|
0.75
|